These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25831765)

  • 1. [Proteasome inhibitors].
    Fuchida S; Shimazaki C
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():267-71. PubMed ID: 25831765
    [No Abstract]   [Full Text] [Related]  

  • 2. [Management of proteasome inhibitor-induced peripheral neuropathy].
    Takamatsu Y
    Nihon Rinsho; 2015 Jan; 73(1):137-41. PubMed ID: 25626319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 4. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on proteasome inhibitors in multiple myeloma.
    Richardson PG
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
    [No Abstract]   [Full Text] [Related]  

  • 6. [I. Proteasome inhibitor for treatment of multiple myeloma].
    Murakami H; Saito T; Handa H
    Gan To Kagaku Ryoho; 2013 May; 40(5):583-8. PubMed ID: 23957065
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advances in proteasome inhibitor-based cancer therapies.
    Dou QP
    Curr Cancer Drug Targets; 2014; 14(6):505. PubMed ID: 25092106
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
    Noonan K; Colson K
    Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel targeted therapy in multiple myeloma].
    Izumi T
    Nihon Rinsho; 2014 Jun; 72(6):1089-93. PubMed ID: 25016809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A; Ryan PY
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.
    Lendvai N; Tsakos I; Devlin SM; Schaffer WL; Hassoun H; Lesokhin AM; Landau H; Korde N; Mailankody S; Smith E; Chung DJ; Koehne G; Shah GL; Alexander A; Patel M; Ballagi A; Grundberg I; Giralt SA; Landgren O
    Leuk Lymphoma; 2018 Aug; 59(8):1981-1985. PubMed ID: 29308691
    [No Abstract]   [Full Text] [Related]  

  • 14. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ; Badros A
    Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing adverse events of multiple myeloma and anti-multiple myeloma treatment: a perspective on carfilzomib.
    Siegel DS
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():2-3. PubMed ID: 25184229
    [No Abstract]   [Full Text] [Related]  

  • 17. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
    Wang H; Guan F; Chen D; Dou QP; Yang H
    Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
    Gallerani E; Zucchetti M; Brunelli D; Marangon E; Noberasco C; Hess D; Delmonte A; Martinelli G; Böhm S; Driessen C; De Braud F; Marsoni S; Cereda R; Sala F; D'Incalci M; Sessa C
    Eur J Cancer; 2013 Jan; 49(2):290-6. PubMed ID: 23058787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.